SEOUL, Jan. 8 (Yonhap) -- South Korean drugmaker Handok Pharmaceuticals Co. said Tuesday that it has entered a US$25 million preferred stock purchase agreement with local player Genexine Inc. to invest in an American drugmaker.
The arrangement allows the two companies to purchase a combined 54 percent share of Rezolute Inc., a clinical stage biopharmaceutical company, officials said.
Handok Pharmaceutical said the purchase is a strategic investment as the company aims to make further inroads into the world's largest biopharmaceutical market.
"We believe the purchase will play a bigger role for Handok to make headway in the United States," CEO Kim Young-jin said in a press release.
Rezolute, established in 2010, specializes in the development of medication to fight metabolic and orphan diseases.
One month into eased social distancing, S. Korea wrestles with cluster infections, cases with unknown routes
Virus outbreak sheds light on overlooked side of highly touted 'fast' delivery services
Livestreaming platform, another alternative tool for retailers in 'non-contact' era
Debate brews over expansion of employment insurance amid coronavirus outbreak
S. Korea shifts toward new normal of everyday quarantine but wary of 'blind spots'